AIEQ · Exit · 1d
weight 0.090% → 0 (exited)·stock down 5.2% in the 30 days before
Jul 1·entry $537.58·now $540.68
+0.58%
since Jul 1
IDXX
GrowthIDEXX LABORATORIES INC
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits.
Close · 3M
-14.93%
Held by 0 AI ETFs
None of the tracked AI ETFs currently hold this name.
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals1
Win rate0% (0/1)
Avg buy return-3.98%
AIEQ · New entry · 1d
weight 0 → 0.070% (new)·stock up 0.5% in the 30 days before
May 3·entry $563.12·now $540.68Fresh
-3.98%
since May 3
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of May 4
AI ETF AIEQ recently made a new entry into IDEXX, suggesting a positive outlook or growth expectation from an algorithmic perspective. This contrasts with the framework's 'Fail' verdict, which identifies significant concerns regarding financial data availability and the current valuation's lack of margin of safety.
- Circle of CompetenceThe animal health diagnostics market generally exhibits stable demand and recurring revenue from consumables, allowing for reasonably predictable long-term cash flow projections within the circle of competence.
- Economic MoatIDEXX likely possesses an economic moat through high switching costs for veterinary practices integrated into its diagnostic platforms and recurring consumable sales.
- ManagementThere is insufficient data provided to assess management's candor, capital allocation discipline, or skin in the game as required by the framework.
- Financial HealthThe provided financials are insufficient to evaluate the 10-year average ROE, operating margin stability, debt manageability, or owner earnings against the framework's strict criteria.
- Margin of SafetyThe current valuation multiples, including a PER of 42.54 and EV/EBITDA of 43.83, suggest a high premium, leaving no apparent margin of safety.
IDEXX passes the initial screens for circle of competence and economic moat, suggesting a fundamentally strong business. However, the lack of comprehensive historical financial data prevents a full assessment of financial health, and the current high valuation multiples indicate a clear absence of a margin of safety, leading to an overall 'Fail' verdict.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.